Screening candidate genes associated with bladder cancer using DNA microarray

Xu,Axiang; Wang,Chunyang; Sun,Shengkun

doi:10.3892/mmr.2014.2667

Screening candidate genes associated with bladder cancer using DNA microarray

Authors:
- Axiang Xu
- Chunyang Wang
- Shengkun Sun
View Affiliations

Affiliations: Department of Urology, PLA General Hospital, Beijing 100853, P.R. China
Published online on: October 15, 2014 https://doi.org/10.3892/mmr.2014.2667
Pages: 3087-3091

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to screen candidate genes that are closely associated with bladder cancer and to select the most distinct candidate target genes in order to provide theoretical evidence and direction for improved treatment of bladder cancer. The gene microarray dataset GSE45184 was downloaded from the Gene Expression Omnibus database. There were a total of six expression prolife microarrays from three pairs of freshly frozen bladder cancer tissues and corresponding normal adjacent tissues. Differentially expressed genes (DEGs) were identified using the limma package in R software and then subjected to further biological information analysis, including hierarchical clustering analysis and gene ontology enrichment analysis. Co‑expression networks and functional interaction networks were established using the up‑ and downregulated genes. Pathway enrichment analysis was then performed for the genes in the functional interaction networks. A total of 522 DEGs were identified, including 223 upregulated and 299 downregulated genes. Functional enrichment analysis of the target genes indicated that downregulated genes were associated with the regulation of biological processes, while the upregulated genes participated in the processes involved in the cell cycle. The functional network of the upregulated genes comprised 1,518 connections and 92 gene nodes that were associated with 10 closely‑related functions, while the network of the downregulated genes consisted of 129 connections and 24 gene nodes involving 11 significantly related functions. Pathway enrichment analysis revealed that the downregulated genes were mainly involved in the mitogen‑activated protein kinase signaling pathway, while the upregulated genes were closely associated with the cell cycle. These DEGs and the relevant cell cycle pathways have the potential to be used as targets for the treatment of bladder cancer.

View Figures

View References

1	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
2	Tsihlias J and Grossman HB: The utility of fibrin/fibrinogen degradation products in superficial bladder cancer. Urol Clin North Am. 27:39–46. 2000. View Article : Google Scholar : PubMed/NCBI
3	Sutcliffe S and Colditz GA: Prostate cancer: is it time to expand the research focus to early-life exposures? Nat Rev Cancer. 13:208–518. 2013. View Article : Google Scholar : PubMed/NCBI
4	Troyer D: Emerging biomarkers in prostate cancer. Aging Health. 2:579–588. 2006. View Article : Google Scholar
5	O’Brien T, Cranston D, Fuggle S, Bicknell R and Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 55:510–513. 1995.PubMed/NCBI
6	Nguyen M, Watanabe H, Budson AE, Richie JP and Folkman J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst. 85:241–242. 1993. View Article : Google Scholar : PubMed/NCBI
7	Chopin DK, Caruelle JP, Colombel M, et al: Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol. 150:1126–1130. 1993.PubMed/NCBI
8	Campbell SC: Advances in angiogenesis research: relevance to urological oncology. J Urol. 158:1663–1674. 1997. View Article : Google Scholar : PubMed/NCBI
9	He W, Cai Q, Sun F, et al: linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer. Biochim Biophys Acta. 1832:1528–1537. 2013. View Article : Google Scholar : PubMed/NCBI
10	Fujita A, Sato JR, de Rodrigues LO, Ferreira CE and Sogayar MC: Evaluating different methods of microarray data normalization. BMC Bioinformatics. 7:4692006. View Article : Google Scholar : PubMed/NCBI
11	Gentleman R, Carey VJ, Huber W, Irizarry RA and Dudoit S: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. 746718470. Springer; New York, NY: 2005, pp. XIX
12	Eisen MB, Spellman PT, Brown PO and Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 95:14863–14868. 1998. View Article : Google Scholar : PubMed/NCBI
13	Saldanha AJ: Java Treeview - extensible visualization of microarray data. Bioinformatics. 20:3246–3248. 2004. View Article : Google Scholar : PubMed/NCBI
14	Obayashi T, Hayashi S, Shibaoka M, Saeki M, Ohta H and Kinoshita K: COXPRESdb: a database of coexpressed gene networks in mammals. Nucleic Acids Res. 36:D77–D82. 2008. View Article : Google Scholar : PubMed/NCBI
15	Sherman BT and Lempicki RA: Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
16	Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009.PubMed/NCBI
17	Evan GI and Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001. View Article : Google Scholar : PubMed/NCBI
18	Ruzinova MB and Benezra R: Id proteins in development, cell cycle and cancer. Trends Cell Biol. 13:410–418. 2003. View Article : Google Scholar : PubMed/NCBI
19	Hartwell LH and Kastan MB: Cell cycle control and cancer. Science. 266:1821–1828. 1994. View Article : Google Scholar : PubMed/NCBI
20	Park MT and Lee SJ: Cell cycle and cancer. J Biochem Mol Biol. 36:60–65. 2003. View Article : Google Scholar
21	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:704–707. 1993. View Article : Google Scholar : PubMed/NCBI
22	Takuwa N and Takuwa Y: Regulation of cell cycle molecules by the Ras effector system. Mol Cell Endocrinol. 177:25–33. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wei Y, Chen YH, Li LY, et al: CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol. 13:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
24	Malumbres M and Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 1:222–231. 2001. View Article : Google Scholar : PubMed/NCBI
25	Tetsu O and McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI
26	Tetsu O and McCormick F: Proliferation of cancer cells despite CDK2 inhibition. Cancer cell. 3:233–245. 2003. View Article : Google Scholar : PubMed/NCBI
27	Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18:2699–2711. 2004. View Article : Google Scholar : PubMed/NCBI
28	LaBaer J, Garrett MD, Stevenson LF, et al: New functional activities for the p21 family of CDK inhibitors. Genes Dev. 11:847–862. 1997. View Article : Google Scholar : PubMed/NCBI
29	Cheng M, Olivier P, Diehl JA, et al: The p21(Cip1) and p27(Kip1) CDK ‘inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J. 18:1571–1583. 1999.
30	Dunn KL, Espino PS, Drobic B, et al: The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem Cell Biol. 83:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
31	Dangle PP, Zaharieva B, Jia H and Pohar KS: Ras-MAPK pathway as a therapeutic target in cancer - emphasis on bladder cancer. Recent Pat Anticancer Drug Discov. 4:125–136. 2009. View Article : Google Scholar : PubMed/NCBI